ナノ医薬品の世界市場レポート 2025年

ナノ医薬品の市場規模は今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は17.8%で、2,163億9,000万米ドルに成長します。予測期間の成長は、慢性疾患の有病率の増加、研究開発の増加、ヘルスケアへの投資の増加、個別化医療への需要の増加、がんの有病率の増加に起因しています。予測期間の主な動向には、ナノテクノロジーと他の新興技術との統合、ナノ対応ドラッグデリバリーの進歩、バイオテクノロジーとゲノミクスの進歩、AI、機械学習、計算モデリングの統合、技術の進歩などがあります。

慢性疾患の有病率の増加は、今後数年間のナノ医薬品市場の成長を促進すると予想されます。がん、糖尿病、心臓病、喘息などの慢性疾患は、一般的に継続的な医療措置と管理を必要とする長期的な疾患です。これらの疾患の有病率上昇の要因としては、不健康な食生活、運動不足、タバコの使用、過度のアルコール摂取、遺伝的素因、環境の影響などが挙げられます。ナノ医薬品は、標的ドラッグデリバリー、バイオアベイラビリティの向上、放出制御、副作用の軽減、高度な併用療法を提供することにより慢性疾患の治療に利用され、これらすべてが治療効果と患者の転帰を改善します。例えば、2022年4月、米国の非営利団体であるNational Association of Chronic Disease Directors（NACDD）は、米国成人の60％近くが少なくとも1つの慢性疾患に罹患しており、約40％が複数の慢性疾患（MCC）に罹患していると報告しました。この蔓延は、2030年までに米国経済に年間2兆ドル、一人当たり8,600ドルの損失をもたらすと予想されています。このため、慢性疾患の増加がナノ医薬品市場の拡大に拍車をかけています。

ナノ医薬品市場の主要企業は、個人、企業、政府向けの通信サービスを強化するため、戦略的パートナーシップを採用するケースが増えています。戦略的パートナーシップとは、企業が互いの強みやリソースを活用し、相互利益と成功を達成することです。例えば、2024年4月、フィンランドを拠点とするナノ粒子医療企業であるNanoform Finland Plcは、日本を拠点とする開発専門商社である株式会社CBCと提携し、Nanoformの高度なナノ医療工学技術のビジネスチャンスを模索しています。この協業は、最先端のナノテクノロジーを活用し、世界中の患者のために医薬品を改善する取り組みにおける重要なマイルストーンとなります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ナノ医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のナノ医薬品市場：成長率分析
• 世界のナノ医薬品市場の実績：規模と成長, 2019-2024
• 世界のナノ医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界ナノ医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のナノ医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リポソーム
• ポリマーミセル
• 固体脂質ナノ粒子
• マイクロエマルジョン
• ナノエマルジョン
• その他の製品タイプ
• 世界のナノ医薬品市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 肺
• その他の投与経路
• 世界のナノ医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 神経学
• 抗炎症
• 抗感染性
• 心血管系
• その他の用途
• 世界のナノ医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 専門薬局
• 調査機関
• その他のエンドユーザー
• 世界のナノ医薬品市場リポソームの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のリポソーム
• ペグ化リポソーム
• カチオン性リポソーム
• アニオン性リポソーム
• 免疫リポソーム
• ステルスリポソーム
• 熱感受性リポソーム
• 世界のナノ医薬品市場、ポリマーミセルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブロック共重合体ミセル
• 両親媒性ポリマーミセル
• 生分解性ポリマーミセル
• ナノ粒子-ポリマーハイブリッドミセル
• pH感受性ミセル
• 熱応答性ミセル
• 世界のナノ医薬品市場固体脂質ナノ粒子（SLN）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のSLN
• ナノ構造脂質キャリア（NLC）
• ドラッグデリバリーのためのSLN
• 化粧品用途向けSLN
• 標的リガンドを有するSLN
• ワクチン投与のためのSLN
• 世界のナノ医薬品市場マイクロエマルジョンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 水中油型（O/W）マイクロエマルジョン
• 油中水型（W/O）マイクロエマルジョン
• 多相マイクロエマルジョン
• ドラッグデリバリーのためのマイクロエマルジョン
• 化粧品用途におけるマイクロエマルジョン
• 有効成分を含むマイクロエマルジョン
• 世界のナノ医薬品市場ナノエマルジョンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 水中油（O/W）ナノエマルジョン
• 油中水型（W/O）ナノエマルジョン
• 非経口投与用ナノエマルジョン
• 経口投与用ナノエマルジョン
• 安定性を高めたナノエマルジョン
• 食品用途におけるナノエマルジョン
• 世界のナノ医薬品市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナノ結晶
• デンドリマー
• ナノ複合材料
• ナノスフィア
• ナノチューブ
• 量子ドット
• 磁性ナノ粒子

第7章 地域別・国別分析

• 世界のナノ医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のナノ医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ナノ医薬品市場：競合情勢
• ナノ医薬品市場：企業プロファイル
  • Selecta Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Novovax Inc.
• OSI Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ナノ医薬品市場2029：新たな機会を提供する国
• ナノ医薬品市場2029：新たな機会を提供するセグメント
• ナノ医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Nanopharmaceuticals are a category of pharmaceutical drugs that leverage nanotechnology to enhance the delivery, targeting, and effectiveness of therapeutic agents. These drugs are formulated at the nanoscale, typically ranging from 1 to 100 nanometers, and are designed to improve drug solubility, stability, bioavailability, and targeted delivery to specific cells or tissues. Nanopharmaceuticals represent an advanced approach in medicine, offering the potential for more precise, effective, and safer treatments across various diseases.

The primary types of nanopharmaceuticals include liposomes, polymeric micelles, solid lipid nanoparticles, microemulsions, nanoemulsions, and others. Liposomes are small, spherical vesicles composed of phospholipids that can encapsulate drugs, enhancing their delivery to targeted cells or tissues. They help protect the drug from degradation and improve its absorption. Nanopharmaceuticals can be administered through various routes, including oral, injectable, topical, pulmonary, and others. Their applications span multiple therapeutic areas such as oncology, neurology, anti-inflammatory, anti-infective, cardiovascular, and more. These drugs are utilized by several end-users, including hospitals and clinics, specialty pharmacies, research institutions, and others.

The nanopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides nanopharmaceuticals market statistics, including nanopharmaceuticals industry global market size, regional shares, competitors with a nanopharmaceuticals market share, detailed nanopharmaceuticals market segments, market trends, and opportunities, and any further data you may need to thrive in the nanopharmaceuticals industry. This nanopharmaceuticals research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nanopharmaceuticals market size has grown rapidly in recent years. It will grow from $95.21 $ billion in 2024 to $112.49 $ billion in 2025 at a compound annual growth rate (CAGR) of 18.2%. The growth in the historic period can be attributed to the demand for effective treatment, growing awareness of nanopharmaceuticals, demand for targeted therapies, increasing incidences of neurodegenerative diseases, and the aging population.

The nanopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $216.39 $ billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to the growing prevalence of chronic diseases, growing research and development, growing investments in healthcare, growing demand for personalized medicine, and increasing prevalence of cancers. Major trends in the forecast period include the integration of nanotechnology with other emerging technologies, advancements in nano-enabled drug delivery, advances in biotechnology and genomics, integration of AI, machine learning and computational modeling, and technological advancement.

The increasing prevalence of chronic diseases is expected to drive the growth of the nanopharmaceuticals market in the coming years. Chronic diseases, such as cancer, diabetes, heart disease, and asthma, are long-term conditions that typically require ongoing medical attention and management. Factors contributing to the rising prevalence of these diseases include unhealthy diets, lack of physical activity, tobacco use, excessive alcohol consumption, genetic predisposition, and environmental influences. Nanopharmaceuticals are utilized in treating chronic diseases by offering targeted drug delivery, enhanced bioavailability, controlled release, reduced side effects, and advanced combination therapies, all of which improve treatment efficacy and patient outcomes. For example, in April 2022, the National Association of Chronic Disease Directors (NACDD), a US-based non-profit organization, reported that nearly 60% of American adults have at least one chronic disease, and around 40% have multiple chronic conditions (MCC). This prevalence is expected to cost the US economy $2 trillion annually, or $8,600 per person, by 2030. Therefore, the growing incidence of chronic diseases is fueling the expansion of the nanopharmaceuticals market.

Major companies in the nanopharmaceuticals market are increasingly adopting strategic partnerships to enhance communication services for individuals, businesses, and governments. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in April 2024, Nanoform Finland Plc, a Finland-based nanoparticle medicine company, joined forces with CBC Co. Ltd., a Japan-based development-focused trading company, to explore opportunities for Nanoform's advanced nanomedicine engineering technologies. This collaboration represents a significant milestone in their efforts to utilize cutting-edge nanotechnology to improve medicines for patients globally.

In February 2022, Merck KGaA, a Germany-based company specializing in healthcare, life sciences, and performance materials, acquired Exelead Inc. for $780 million. This acquisition aims to strengthen Merck's capabilities in advanced drug delivery, particularly by integrating Exelead's expertise in lipid nanoparticle technology, which is essential for developing and producing innovative therapies, including mRNA-based treatments. Exelead Inc. is a US-based company that manufactures complex injectable formulations, including lipid nanoparticle (LNP) technology.

Major companies operating in the nanopharmaceuticals market are Selecta Biosciences Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Abvie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Novovax Inc., OSI Pharmaceuticals Inc., Par Pharmaceutial Inc., Samyang Biopharm Corporation

North America was the largest region in the global nanopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nanopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nanopharmaceuticals market consists of sales of dendritic nanoparticles, quantum dots, micellar nanoparticles, and gene delivery systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nanopharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nanopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nanopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nanopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Liposomes; Polymeric Micelles; Solid Lipid Nanoparticles; Microemulsion; Nanoemulsion; Other Product Types
• 2) By Route Of Administration: Oral; Injectable; Topical; Pulmonary; Other Routes Of Administration
• 3) By Application: Oncology; Neurology; Anti-inflammatory; Anti-infective; Cardiovascular; Other Applications
• 4) By End-User: Hospitals And Clinics; Specialty Pharmacies; Research Institutions; Other End Users
• Subsegments:
• 1) By Liposomes: Conventional Liposomes; Pegylated Liposomes; Cationic Liposomes; Anionic Liposomes; Immunoliposomes; Stealth Liposomes; Thermosensitive Liposomes;
• 2) By Polymeric Micelles: Block Copolymer Micelles; Amphiphilic Polymer Micelles; Biodegradable Polymeric Micelles; Nanoparticle-Polymer Hybrid Micelles; pH-Sensitive Micelles; Thermo-responsive Micelles
• 3) By Solid Lipid Nanoparticles (SLNs): Conventional SLNs; Nanostructured Lipid Carriers (NLCs); SLNs for Drug Delivery; SLNs for Cosmetic Applications; SLNs with Targeting Ligands; SLNs for Vaccine Delivery
• 4) By Microemulsion: Oil-in-Water (O/W) Microemulsions; Water-in-Oil (W/O) Microemulsions; Multi-Phase Microemulsions; Microemulsions for Drug Delivery; Microemulsions in Cosmetic Applications; Microemulsions with Active Ingredients
• 5) By Nanoemulsion: Oil-in-Water (O/W) Nanoemulsions; Water-in-Oil (W/O) Nanoemulsions; Nanoemulsions for Parenteral Administration; Nanoemulsions for Oral Delivery; Nanoemulsions with Enhanced Stability; Nanoemulsions in Food Applications
• 6) By Other Product Types: Nanocrystals; Dendrimers; Nanocomposites; Nanospheres; Nanotubes; Quantum Dots; Magnetic Nanoparticles
• Companies Mentioned: Selecta Biosciences Inc.; Pfizer Inc.; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nanopharmaceuticals Market Characteristics

3. Nanopharmaceuticals Market Trends And Strategies

4. Nanopharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nanopharmaceuticals Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nanopharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nanopharmaceuticals Market Growth Rate Analysis
• 5.4. Global Nanopharmaceuticals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nanopharmaceuticals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nanopharmaceuticals Total Addressable Market (TAM)

6. Nanopharmaceuticals Market Segmentation

• 6.1. Global Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liposomes
• Polymeric Micelles
• Solid Lipid Nanoparticles
• Microemulsion
• Nanoemulsion
• Other Product Types
• 6.2. Global Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• Pulmonary
• Other Routes Of Administration
• 6.3. Global Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Neurology
• Anti-inflammatory
• Anti-infective
• Cardiovascular
• Other Applications
• 6.4. Global Nanopharmaceuticals Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Specialty Pharmacies
• Research Institutions
• Other End Users
• 6.5. Global Nanopharmaceuticals Market, Sub-Segmentation Of Liposomes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Liposomes
• Pegylated Liposomes
• Cationic Liposomes
• Anionic Liposomes
• Immunoliposomes
• Stealth Liposomes
• Thermosensitive Liposomes
• 6.6. Global Nanopharmaceuticals Market, Sub-Segmentation Of Polymeric Micelles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Block Copolymer Micelles
• Amphiphilic Polymer Micelles
• Biodegradable Polymeric Micelles
• Nanoparticle-Polymer Hybrid Micelles
• pH-Sensitive Micelles
• Thermo-responsive Micelles
• 6.7. Global Nanopharmaceuticals Market, Sub-Segmentation Of Solid Lipid Nanoparticles (SLNs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional SLNs
• Nanostructured Lipid Carriers (NLCs)
• SLNs for Drug Delivery
• SLNs for Cosmetic Applications
• SLNs with Targeting Ligands
• SLNs for Vaccine Delivery
• 6.8. Global Nanopharmaceuticals Market, Sub-Segmentation Of Microemulsion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oil-in-Water (O/W) Microemulsions
• Water-in-Oil (W/O) Microemulsions
• Multi-Phase Microemulsions
• Microemulsions for Drug Delivery
• Microemulsions in Cosmetic Applications
• Microemulsions with Active Ingredients
• 6.9. Global Nanopharmaceuticals Market, Sub-Segmentation Of Nanoemulsion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oil-in-Water (O/W) Nanoemulsions
• Water-in-Oil (W/O) Nanoemulsions
• Nanoemulsions for Parenteral Administration
• Nanoemulsions for Oral Delivery
• Nanoemulsions with Enhanced Stability
• Nanoemulsions in Food Applications
• 6.10. Global Nanopharmaceuticals Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nanocrystals
• Dendrimers
• Nanocomposites
• Nanospheres
• Nanotubes
• Quantum Dots
• Magnetic Nanoparticles

7. Nanopharmaceuticals Market Regional And Country Analysis

• 7.1. Global Nanopharmaceuticals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nanopharmaceuticals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nanopharmaceuticals Market

• 8.1. Asia-Pacific Nanopharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nanopharmaceuticals Market

• 9.1. China Nanopharmaceuticals Market Overview
• 9.2. China Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nanopharmaceuticals Market

• 10.1. India Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nanopharmaceuticals Market

• 11.1. Japan Nanopharmaceuticals Market Overview
• 11.2. Japan Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nanopharmaceuticals Market

• 12.1. Australia Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nanopharmaceuticals Market

• 13.1. Indonesia Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nanopharmaceuticals Market

• 14.1. South Korea Nanopharmaceuticals Market Overview
• 14.2. South Korea Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nanopharmaceuticals Market

• 15.1. Western Europe Nanopharmaceuticals Market Overview
• 15.2. Western Europe Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nanopharmaceuticals Market

• 16.1. UK Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nanopharmaceuticals Market

• 17.1. Germany Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nanopharmaceuticals Market

• 18.1. France Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nanopharmaceuticals Market

• 19.1. Italy Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nanopharmaceuticals Market

• 20.1. Spain Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nanopharmaceuticals Market

• 21.1. Eastern Europe Nanopharmaceuticals Market Overview
• 21.2. Eastern Europe Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nanopharmaceuticals Market

• 22.1. Russia Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nanopharmaceuticals Market

• 23.1. North America Nanopharmaceuticals Market Overview
• 23.2. North America Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nanopharmaceuticals Market

• 24.1. USA Nanopharmaceuticals Market Overview
• 24.2. USA Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nanopharmaceuticals Market

• 25.1. Canada Nanopharmaceuticals Market Overview
• 25.2. Canada Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nanopharmaceuticals Market

• 26.1. South America Nanopharmaceuticals Market Overview
• 26.2. South America Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nanopharmaceuticals Market

• 27.1. Brazil Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nanopharmaceuticals Market

• 28.1. Middle East Nanopharmaceuticals Market Overview
• 28.2. Middle East Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nanopharmaceuticals Market

• 29.1. Africa Nanopharmaceuticals Market Overview
• 29.2. Africa Nanopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nanopharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nanopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nanopharmaceuticals Market Competitive Landscape And Company Profiles

• 30.1. Nanopharmaceuticals Market Competitive Landscape
• 30.2. Nanopharmaceuticals Market Company Profiles
  • 30.2.1. Selecta Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nanopharmaceuticals Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb Company
• 31.4. AstraZeneca plc
• 31.5. Abbott Laboratories
• 31.6. Novartis AG
• 31.7. GlaxoSmithKline plc
• 31.8. Eli Lilly and Company
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Amgen Inc.
• 31.11. Stryker Corporation
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Astellas Pharma Inc.
• 31.14. Novovax Inc.
• 31.15. OSI Pharmaceuticals Inc.

32. Global Nanopharmaceuticals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nanopharmaceuticals Market

34. Recent Developments In The Nanopharmaceuticals Market

35. Nanopharmaceuticals Market High Potential Countries, Segments and Strategies

• 35.1 Nanopharmaceuticals Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nanopharmaceuticals Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nanopharmaceuticals Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer